Brewin Dolphin LTD Prothena Corp Public LTD CO Transaction History

Brewin Dolphin LTD

  • $2.08 Billion
  • Q2 2022

A detailed history of Brewin Dolphin LTD transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Brewin Dolphin LTD holds 16 shares of PRTA stock, worth $246. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 16 -0.0%
Holding current value
$246
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Nov 14, 2022
BUY
$42.11 - $73.26 $673 - $1,172
16 New
16 $1,000
Q1 2021

Nov 09, 2023
BUY
$11.0 - $28.24 $5,500 - $14,120
500 Added 1724.14%
529 $13.3 Million
Q3 2020

Nov 09, 2023
SELL
$9.93 - $13.47 $10,287 - $13,954
-1,036 Reduced 97.28%
29 $290,000
Q2 2020

Nov 09, 2023
SELL
$9.56 - $12.51 $86 - $112
-9 Reduced 0.84%
1,065 $11.1 Million
Q1 2020

Nov 09, 2023
SELL
$7.54 - $15.77 $1,470 - $3,075
-195 Reduced 15.37%
1,074 $11.5 Million
Q2 2018

Nov 09, 2023
BUY
$10.99 - $44.21 $10,286 - $41,380
936 Added 281.08%
1,269 $18.5 Million
Q1 2018

Nov 09, 2023
BUY
$27.95 - $45.04 $2,795 - $4,504
100 Added 42.92%
333 $12.2 Million
Q4 2017

Nov 09, 2023
SELL
$35.44 - $63.76 $3,544 - $6,376
-100 Reduced 30.03%
233 $8.74 Million
Q3 2017

Nov 09, 2023
BUY
$53.83 - $67.75 $17,064 - $21,476
317
333 $21.6 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $723M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Brewin Dolphin LTD Portfolio

Follow Brewin Dolphin LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brewin Dolphin LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email